Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

Summary

This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.

Conditions

• Childhood Central Nervous System Germ Cell Tumor
• Childhood Extragonadal Germ Cell Tumor
• Childhood Hepatoblastoma
• Childhood Hepatocellular Carcinoma
• Childhood High-grade Cerebral Astrocytoma
• Childhood Low-grade Cerebral Astrocytoma
• Childhood Malignant Ovarian Germ Cell Tumor
• Childhood Malignant Testicular Germ Cell Tumor
• Childhood Teratoma
• Recurrent Adrenocortical Carcinoma
• Recurrent Childhood Brain Stem Glioma
• Recurrent Childhood Cerebellar Astrocytoma
• Recurrent Childhood Cerebral Astrocytoma
• Recurrent Childhood Ependymoma
• Recurrent Childhood Liver Cancer
• Recurrent Childhood Malignant Germ Cell Tumor
• Recurrent Childhood Rhabdomyosarcoma
• Recurrent Childhood Soft Tissue Sarcoma
• Recurrent Childhood Visual Pathway and Hypothalamic Glioma
• Recurrent Colon Cancer
• Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
• Recurrent Nasopharyngeal Cancer
• Recurrent Neuroblastoma
• Recurrent Osteosarcoma
• Recurrent Rectal Cancer
• Recurrent Renal Cell Cancer

Interventions

DRUG

oxaliplatin

Given IV

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Orren Beaty · Children's Oncology Group

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Max Age

21 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2004-10-31

Primary Completion

2006-02-28

Countries

• United States

Study Locations